Gossamer Bio, Inc. GOSS
10.94
0.01
0.09%
as of 25 Sep
- Market cap
- $66.8M
- P/E
- 0.0×
Follow GOSS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1,107.65% | 365.33% | 215.10% | 178.72% | |
| (55.80%) | (69.89%) | (88.11%) | (78.81%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(110.02%) | (163.39%) | (264.94%) | 192.64% | |
Average Days of Receivables |
76.59 | 92.07 | 60.81 | 41.82 | |
Free Cash Flow per Share |
(55.66) | (59.98) | (58.18) | (40.65) | |
Free Cash Flow |
(158.61) | (171.34) | (170.26) | (162.63) | |
Capital Expenditures |
(0.18) | (0.08) | — | — | |
Piotroski F-Score |
2.00 | 2.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(53.50%) | (80.53%) | (124.74%) | 18,954.08% | |
Accounts Receivable Turnover |
5.57 | 5.52 | 7.01 | 7.79 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.02) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
366.10% | 359.17% | 322.54% | 307.71% | |
Selling, General and Administrative Expense of Revenue |
82.00% | 77.64% | 85.92% | 89.97% | |
Share Based Compensation of Revenue |
28.65% | 21.78% | 26.03% | 26.89% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.01 | 1.01 | 0.94 | 1.30 | |
Depreciation/Fixed assets |
(96.26) | (82.67) | (57.29) | 53.11 | |
Capex/Depreciation |
0.03 | 0.01 | 0.00 | 0.00 | |
Revenue per Share |
15.46 | 16.97 | 18.98 | 13.32 | |
Operating CF per Share |
(55.59) | (59.96) | (58.18) | (40.65) | |
Capex per Share |
(0.06) | (0.03) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(354.50%) | (351.49%) | (324.82%) | (235.00%) |
Columns are period end dates